Market capitalization | JPY1.01t |
Enterprise Value | JPY879.59b |
PER (TTM) P/E ratio | 22.37 |
EV/FCF (TTM) EV/FCF | 16.63 |
EV/Sales (TTM) EV/Sales | 3.68 |
P/S ratio (TTM) P/S ratio | 4.24 |
P/B ratio (TTM) P/B ratio | 2.88 |
Dividend yield | 1.27% |
Last dividend (FY23) | JPY19.00 |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
14 Analysts have issued a M3 forecast:
14 Analysts have issued a M3 forecast:
Mar '24 |
+/-
%
|
||
Turnover | 238,883 238,883 |
3%
3%
|
|
Gross income | 140,531 140,531 |
4%
4%
|
|
EBITDA | 74,406 74,406 |
4%
4%
|
EBIT (operating result) EBIT | 65,528 65,528 |
6%
6%
|
Net profit | 45,271 45,271 |
8%
8%
|
Figures in millions JPY.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
M3, Inc. engages in the provision of medical related services through the Internet. It operates through the following segments: Medical Portal, Evidence Solutions, Overseas, Clinical Platform, and Others. The Medical Portal segment provides the medical-related marketing support and research services. The Evidence Solutions segment includes clinical research support business, medical clinical trials management, and management support business. The Overseas segment offers marketing support and research services for medical-related firms in the United States, the United Kingdom, and South Korea. The Clinical Platform segment engages in the development, sale and support of electronic medical records. The Others segment offers information services for medical institutions and prescription drug advertising business. The company was founded on September 29, 2000 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Itaru Tanimura |
Employees | 12,100 |
Founded | 2000 |
Website | corporate.m3.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.